Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Total parenteral nutrition (TPN) solution providing essential amino acids, electrolytes, and dextrose. Dextrose supplies calories to spare protein catabolism; amino acids support protein synthesis; electrolytes maintain acid-base and fluid balance.
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
Intravenous administration of 1.5-2.5 L/day in divided doses, adjusted based on metabolic needs, fluid status, and electrolytes. Typical rate: 100-200 mL/hour via central line.
None Documented
None Documented
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Not applicable as a single entity; components have various half-lives. Glucose has a plasma half-life of approximately 1.5-2 hours. Amino acids have variable half-lives (minutes to hours). Clinical context: continuous infusion maintains steady state.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
Amino acids and dextrose are metabolized; excess nitrogen is excreted as urea via renal route (approximately 90% of nitrogen output). Electrolytes are excreted renally. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution